Cancer glossary
Pseudoprogression on immunotherapy: what it is and how often it occurs
Pseudoprogression is when a tumor first looks bigger on CT and then shrinks. How often it happens on immunotherapy and how it is told apart from real growth.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026
In short
Pseudoprogression is when, during immunotherapy, a tumor first looks bigger on scans or new lesions appear, and then the disease shrinks or stabilizes. It is uncommon, so any growth is first treated as possible true progression.
How it appears in your report
- “Increase in lesion size; given ongoing immunotherapy, pseudoprogression cannot be excluded”.
- “iUPD per iRECIST” — unconfirmed progression that needs reassessment.
- “iCPD” — progression confirmed on the next scan.
What it means
The usual explanation: immune cells move into the tumor, causing inflammation and swelling, so the lesion looks bigger on CT even though there are no more cancer cells.
| Data | Source |
|---|---|
| Frequency about 6% (17 studies, 3,402 patients) | Meta-analysis, Radiology, 2020 |
| Melanoma 6.4%, non-small cell lung cancer 5.0%, kidney and urothelial cancer 7.0% | Same |
Under iRECIST, the first progression on immunotherapy is treated as unconfirmed (iUPD). A repeat scan is recommended 4–8 weeks later: if growth continues or new lesions appear, progression is confirmed (iCPD). The iRECIST authors stress that these are rules for handling data in trials, not instructions for managing an individual patient.
Does it affect treatment
If you are clinically stable, your doctor may suggest continuing immunotherapy until the next scan instead of changing treatment straight away. If you are getting worse, symptoms are increasing or lesions are growing fast, waiting is usually not appropriate. Where the line falls is decided by your treating doctor or a tumor board. More about the treatment itself in the article on immunotherapy. If your report says progression and you doubt the conclusion, I can review your scans and records as a second opinion.
Questions to ask your doctor
- Do you think this growth could be pseudoprogression, and why?
- When is the next scan, and what will we do for each possible result?
- Which symptoms should make me contact you sooner?
Sources
- Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis — Park H.J. et al., Radiology, 2020
- iRECIST guidelines — RECIST Working Group / EORTC, 2017
- RECIST 1.1 — RECIST Working Group / EORTC; Eisenhauer E.A. et al., European Journal of Cancer, 2009
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
